Biogen BIIB FUMADERM — Revenue
Discontinued — last reported Q4 '22
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-K, filed February 15, 2023, on SEC EDGAR. View the filing →
Ask your AI about Biogen's fumaderm — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's FUMADERM — revenue?
- Biogen (BIIB) reported FUMADERM — revenue of $1.8M in Q4 2022.
- How has Biogen's FUMADERM — revenue changed year-over-year?
- Biogen's FUMADERM — revenue decreased by 33.3% year-over-year, from $2.7M to $1.8M.
- What does FUMADERM — revenue mean?
- The total revenue generated from sales of the psoriasis medication Fumaderm.
- How do you interpret FUMADERM — revenue?
- An increase in revenue signals strong market adoption, effective pricing strategies, or expanded patient access, while a decrease may indicate increased competition, patent expirations, or shifts in clinical treatment guidelines.
- How does FUMADERM — revenue compare across companies?
- Comparable to revenue streams from legacy or niche dermatological and immunological specialty drugs at other biopharmaceutical companies.